Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Non-Current Assets (2018 - 2025)

Historic Non-Current Assets for Revolution Medicines (RVMD) over the last 8 years, with Q3 2025 value amounting to $274.4 million.

  • Revolution Medicines' Non-Current Assets rose 4926.09% to $274.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $989.0 million, marking a year-over-year increase of 3563.72%. This contributed to the annual value of $230.7 million for FY2024, which is 2644.66% up from last year.
  • Revolution Medicines' Non-Current Assets amounted to $274.4 million in Q3 2025, which was up 4926.09% from $253.1 million recorded in Q2 2025.
  • In the past 5 years, Revolution Medicines' Non-Current Assets ranged from a high of $274.4 million in Q3 2025 and a low of $111.4 million during Q3 2021
  • Its 5-year average for Non-Current Assets is $172.0 million, with a median of $151.7 million in 2022.
  • Per our database at Business Quant, Revolution Medicines' Non-Current Assets plummeted by 65.26% in 2021 and then surged by 4926.09% in 2025.
  • Revolution Medicines' Non-Current Assets (Quarter) stood at $148.2 million in 2021, then rose by 2.38% to $151.7 million in 2022, then increased by 20.22% to $182.4 million in 2023, then grew by 26.45% to $230.7 million in 2024, then grew by 18.97% to $274.4 million in 2025.
  • Its Non-Current Assets stands at $274.4 million for Q3 2025, versus $253.1 million for Q2 2025 and $230.8 million for Q1 2025.